Cargando…

Long-Term Real-World Effectiveness of Aripiprazole Once-Monthly. Treatment Persistence and Its Correlates in the Italian and Spanish Clinical Practice: A Pooled Analysis

BACKGROUND: One of the most significant risk factors for relapse and hospitalization in schizophrenia is non-adherence to antipsychotic medications, very common in patients with schizophrenia. The aim of this analysis was to evaluate the treatment persistence to aripiprazole once-monthly (AOM) and t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Olivares, José Manuel, Fagiolini, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Psychiatry
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096029/ https://www.ncbi.nlm.nih.gov/pubmed/35573364 http://dx.doi.org/10.3389/fpsyt.2022.877867

Ejemplares similares

Healthcare resource use and costs reduction with aripiprazole once-monthly in schizophrenia: AMBITION, a real-world study
por: Sanchez-Gistau, Vanessa, et al.
Publicado: (2023)

Real-world effectiveness of aripiprazole once-monthly REACT study: Pooled analysis of two noninterventional studies
por: Schöttle, Daniel, et al.
Publicado: (2022)

Treatment persistence with aripiprazole once monthly: a 4-year follow-up
por: Fagiolini, Andrea, et al.
Publicado: (2022)

Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study
por: Olivares, José Manuel, et al.
Publicado: (2021)

Predictors of persistence in patients with schizophrenia treated with aripiprazole once-monthly long-acting injection in the Spanish clinical practice: a retrospective, observational study – CORRIGENDUM
por: Olivares, José Manuel, et al.
Publicado: (2021)

Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study)
por: Oluboka, Oloruntoba, et al.
Publicado: (2023)

Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
por: Schöttle, Daniel, et al.
Publicado: (2018)

Correction to: Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study
por: Schöttle, Daniel, et al.
Publicado: (2018)

Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting
por: Hodgson, Richard E
Publicado: (2019)

Schizophrenia relapse and the clinical usefulness of once-monthly aripiprazole depot injection
por: Wang, Sheng-Min, et al.
Publicado: (2014)

Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting [Corrigendum]
Publicado: (2019)

Symptomatic stability with aripiprazole once-monthly: efficacy analyses from acute and long-term studies
por: Madera, Jessica J, et al.
Publicado: (2019)

We Really Need Clear Guidelines and Recommendations for Safer and Proper Use of Aripiprazole and Risperidone in a Pediatric Population: Real-World Analysis of EudraVigilance Database
por: Rafaniello, Concetta, et al.
Publicado: (2020)

Population Pharmacokinetic Modeling and Exposure‐Response Analysis for Aripiprazole Once Monthly in Subjects With Schizophrenia
por: Wang, Xiaofeng, et al.
Publicado: (2022)

The effect of switching from oral low-dose aripiprazole to aripiprazole once-monthly 300 mg on the quality of life in three patients with schizophrenia
por: Suzuki, Hidenobu, et al.
Publicado: (2017)

The effect of aripiprazole once-monthly on personal and social functioning: post hoc analyses of acute and long-term studies
por: Peters-Strickland, Timothy, et al.
Publicado: (2019)

Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate: results from QUALIFY
por: Potkin, Steven G., et al.
Publicado: (2017)

Taiwan Expert Consensus Recommendations for Switching to Aripiprazole Long-Acting Once-Monthly in Patients with Schizophrenia
por: Liang, Chih-Sung, et al.
Publicado: (2021)

BPRS domains, items and subgroups analyses, and CGI-I ratings in pooled data from non-interventional studies of aripiprazole once-monthly in schizophrenia (REACT study)
por: Schöttle, Daniel, et al.
Publicado: (2023)

Clinical Features and Outcomes of 124 Italian Patients With Treatment Resistant Depression: A Real-World, Prospective Study
por: Perugi, Giulio, et al.
Publicado: (2021)

The Treatment of Adult Bipolar Disorder with Aripiprazole: A Systematic Review
por: Muneer, Ather
Publicado: (2016)

Does the Time of Drug Administration Alter the Metabolic Risk of Aripiprazole?
por: Chipchura, Danielle A., et al.
Publicado: (2018)

Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia
por: Kane, John M., et al.
Publicado: (2013)

Efficacy and safety of aripiprazole once-monthly in obese and nonobese patients with schizophrenia: a post hoc analysis
por: De Hert, Marc, et al.
Publicado: (2015)

S233. EVOLUTION OF THE FUNCIONING AND ATTITUDES TO MEDICATION IN A SAMPLE WITH EARLY PSYCHOSIS IN TREATMENT WITH ARIPIPRAZOLE ONCE-MONTHLY
por: Soto, Marta, et al.
Publicado: (2018)

Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration
por: Raoufinia, Arash, et al.
Publicado: (2017)

Efficacy and tolerability Aripiprazole once-monthly long-acting injectable in schizophrenia. Two-injection start regimen
por: Romero Guillena, S.L., et al.
Publicado: (2022)

Aripiprazole in bipolar disorder: clinical strategies to maximize efficacy and tolerability
por: Fagiolini, Andrea
Publicado: (2010)

Successful high dose antipsychotic treatment with cariprazine in patients on the schizophrenia spectrum: Real-world evidence from a Spanish hospital setting
por: Galmes, Lluis Niell, et al.
Publicado: (2023)

Aripiprazole once-monthly 400 mg for long-term maintenance treatment of schizophrenia: a 52-week open-label study
por: Peters-Strickland, Timothy, et al.
Publicado: (2015)

Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
por: Oya, Kazuto, et al.
Publicado: (2015)

Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia
por: Wilson, Michele, et al.
Publicado: (2016)

Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis
por: Kane, John M., et al.
Publicado: (2015)

Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly
por: Biagi, Enrico, et al.
Publicado: (2017)

Aripiprazole Long-Acting Injection During First Episode Schizophrenia—An Exploratory Analysis
por: Giordano, Gloria, et al.
Publicado: (2020)

Family functioning and personal growth in Italian caregivers living with a family member affected by schizophrenia: Results of an add-on study of the Italian network for research on psychoses
por: Roncone, Rita, et al.
Publicado: (2023)

Differential Effects of Aripiprazole and Amisulpride on Negative and Cognitive Symptoms in Patients With First-Episode Psychoses
por: Nielsen, Mette Ødegaard, et al.
Publicado: (2022)

Oculogyric Crisis Due to Aripiprazole Ingestion as a Suicide Attempt: A Case Report
por: Bafarat, Ammar, et al.
Publicado: (2023)

Attitudes of Italian Psychiatrists Toward the Evaluation of Physical Comorbidities and Sexual Dysfunction in Patients With Schizophrenia. Implications for Clinical Practice
por: Monteleone, Palmiero, et al.
Publicado: (2019)

Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study
por: Calabrese, Joseph R., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_75o49i7otdijqspo2kavm1ero6